secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0000950170-24-073998
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid reports Takeda's Ph3 soticlestat misses primary endpoints; pipeline and cash runway update
--------------------------------------------------------------------------------

- Takeda's Phase 3 SKYLINE in Dravet syndrome narrowly missed primary endpoint (p=0.06) but showed significant secondary endpoints (p≤0.008).
- Takeda's Phase 3 SKYWAY in Lennox-Gastaut syndrome missed primary endpoint; safety profile consistent.
- Ovid's cash runway expected into H1 2026; pipeline milestones include OV888 Phase 2 start H2 2024, OV329 data H2 2024, OV350 IND H2 2024.
- Takeda will discuss data with regulators; Ovid will update guidance on potential milestones/royalties afterward.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000095017024073998/0000950170-24-073998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000095017024073998/ovid-20240617.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer